U.S. FDA approves bristol-myers squibb devens biologics manufacturing facility for production of orencia (abatacept) Full Text
Bristol Myers-Squibb, 05/16/2012
Bristol–Myers Squibb Company announced that the U.S. Food and Drug Administration (FDA) has approved the company's biologics manufacturing facility in Devens, Massachusetts for commercial production of ORENCIA (abatacept).



